Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia

NCT00586209 is registered in ClinicalTrials.gov with Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center as lead sponsor.

NCT NCT00586209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00586209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase
Phase 2
Overall status
Terminated
Start date
February 6, 2004
Completion date
November 30, 2009
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anemia, thalassemia